May Lauren T, Christopoulos Arthur
Department of Pharmacology, University of Melbourne, Victoria 3010, Australia.
Curr Opin Pharmacol. 2003 Oct;3(5):551-6. doi: 10.1016/s1471-4892(03)00107-3.
Allosteric modulators of G-protein-coupled receptors (GPCRs) interact with binding sites on the receptor that are topographically distinct from the orthosteric site recognized by the receptor's endogenous agonist. Allosteric modulators offer several advantages over standard orthosteric drugs, including the potential for greater receptor subtype selectivity. To date, the current paucity of clinically available allosteric drugs reflects the bias of traditional radioligand binding assays towards the detection of orthosteric effects. However, the advent of new cell-based high-throughput functional assays has led to an increased detection of allosteric GPCR ligands. The current challenge for modulator-based GPCR drug discovery is the optimization of both binding and functional assays to better detect and validate allosteric ligands.
G蛋白偶联受体(GPCRs)的变构调节剂与受体上的结合位点相互作用,这些结合位点在拓扑结构上与受体内源性激动剂识别的正构位点不同。与标准的正构药物相比,变构调节剂具有几个优势,包括更高的受体亚型选择性潜力。迄今为止,临床上可用的变构药物较少,这反映了传统放射性配体结合测定法对正构效应检测的偏向性。然而,基于细胞的新的高通量功能测定法的出现,使得变构GPCR配体的检测有所增加。基于调节剂的GPCR药物发现目前面临的挑战是优化结合和功能测定法,以更好地检测和验证变构配体。